This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Today's Health Winners and Losers

Shares of Genomic Health (GHDX - Get Report) were among the worst-performing health-related stocks Monday, slumping 17% after Piper Jaffray downgraded the stock to market perform from outperform. The firm also cut its price target on the stock to $14.50 from $18.50.

Piper Jaffray cited increased regulatory risk concerning the company's only product, a breast cancer test called Oncotype DX, for the downgrade. Until the regulatory status of the test is cleared up, the firm said, an overhang on the stock could last for some six to 10 months. In late January, the Food and Drug Administration sent a letter to Genomic inviting the company to meet with regulators to discuss the regulatory status of the test and discuss ways in which the company could fulfill any FDA premarket review requirements that might apply. Shares recently were trading down $2.53 to $12.07.

Oscient Pharmaceuticals (OSCI) fell 8% Monday, even though the drugmaker posted better-than-expected fourth-quarter results. The company reported a loss of $17.1 million, or 22 cents a share, on revenue of $9.5 million. Analysts polled by Thomson First Call expected a loss of 29 cents a share and revenue of $9.1 million. A year earlier, the company recorded a loss of $32.3 million, or 43 cents a share, on revenue of $2.7 million. The company said its most recent results were fueled by strong sales of Factive tablets and Testim testosterone gel. Shares recently traded at $2, down 18 cents.

Shares of Medicines Co. (MDCO - Get Report) fell 2% after the drug developer announced the resignation of its chief financial officer. The company said Steve Koehler, who had served as CFO for four years, will step down on March 17 to take a position with a pharmaceutical company. Koehler will be replaced by Glenn Sblendorio, who most recently served as chief financial officer at Eyetech Pharmaceuticals, which was acquired in November by OSI Pharmaceuticals (OSIP). Medicines Co. shares were trading down 49 cents to $19.62.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
IMDC $0.03 2.81%
AGN $235.41 -0.11%
COHR $66.18 1.04%
GHDX $32.33 4.02%
INSM $20.33 7.00%

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs